Pharmacological blockade of microglial activation [35–37] or knockdown of cytokines, such as IL-1 [38], demonstrates that prevention of microglial activation attenuates some of the degeneration seen in models of PD. The gene discussed is IL1B; the disease is Parkinson disease.